Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sets New 52-Week High – Still a Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) reached a new 52-week high during trading on Tuesday . The company traded as high as $10.50 and last traded at $10.35, with a volume of 37248 shares trading hands. The stock had previously closed at $10.00.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Price Performance

The company has a market cap of $24.65 billion, a P/E ratio of 52.55 and a beta of 1.02. The company has a fifty day simple moving average of $9.50 and a 200-day simple moving average of $9.25. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $6.01 billion during the quarter. On average, sell-side analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current year.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.